Gastroenteropancreatic Neuroendocrine Tumors

• CLINICAL_TRIALS trial_result · 2025-01-28
  Clinical Trial Update: Asian Investigation of Lanreotide Autogel® in the Management of GEP-NETs

  A completed Asian trial evaluating Lanreotide Autogel for Gastroenteropancreatic neuroendocrine tumors. The snippet notes completion but doe…

• CLINICAL_TRIALS trial_result · 2025-01-24
  Clinical Trial Update: Post-Authorization Safety Study (PASS) of LysaKare® in Adult Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients [Phase 4]

  This document reports the results of a Phase 4 post-authorization safety study of LysaKare in adults with Gastroenteropancreatic neuroendocr…

• CLINICAL_TRIALS trial_result · 2022-12-06
  Clinical Trial Update: TEMCAP in Grade 3 and Low Ki-67 Gastroenteropancreatic Neuroendocrine Tumors [Phase 2]

  Phase 2 trial update for TEMCAP in grade 3 and low Ki-67 gastroenteropancreatic neuroendocrine tumors has completed.

• CLINICAL_TRIALS trial_result · 2022-11-10
  Clinical Trial Update: 177Lutetium-octreotate Treatment Prediction Using Multimodality Imaging in Refractory NETs [Phase 3]

  Phase 3 trial evaluating Lutetium-177 dotatate treatment prediction using multimodality imaging in refractory gastroenteropancreatic neuroen…

• CLINICAL_TRIALS trial_result · 2022-10-14
  Clinical Trial Update: [68 Ga]-DOTANOC PET/CT in GEP-NETs [Phase 2, Phase 3]

  A Phase 2/Phase 3 trial evaluating [68 Ga]-DOTANOC PET/CT imaging in gastroenteropancreatic neuroendocrine tumors has completed.

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• CLINICAL_TRIALS trial_result · 2022-09-28
  Clinical Trial Update: Study of Pembrolizumab With Lanreotide Depot for Gastroenteropancreatic Neuroendocrine Tumors [Phase 1, Phase 2]

  Phase 1/2 trial evaluating pembrolizumab in combination with lanreotide depot for gastroenteropancreatic neuroendocrine tumors has completed…

• CLINICAL_TRIALS trial_result · 2020-02-07
  Clinical Trial Update: Efficacy and Safety of 177Lu-Dotatate PRRT in Metastatic GEP-NEN Patients [Phase 2]

  Phase 2 trial update evaluating efficacy and safety of 177Lu-Dotatate PRRT in metastatic gastroenteropancreatic neuroendocrine tumors.

• CLINICAL_TRIALS trial_result · 2019-10-02
  Clinical Trial Update: 68Ga-OPS202 Study for Diagnostic Imaging of GEP NET [Phase 1, Phase 2]

  Clinical trial update for 68Ga-OPS202 imaging agent in gastroenteropancreatic neuroendocrine tumors; study completed with results posted.

• CLINICAL_TRIALS trial_result · 2016-09-07
  Clinical Trial Update: Diagnostic Accuracy of Gallium-68-DOTATATE PET/CT Compared to Indium-111-pentetreotide Scintigraphy (SPECT/CT) for Gastroenteropancreatic Neuroendocrine Tumors [Phase 1, Phase 2]

  A terminated Phase 1/2 study evaluated the diagnostic accuracy of Gallium-68-DOTATATE PET/CT compared with Indium-111-pentetreotide SPECT/CT…